PT-141, known clinically as Bremelanotide, is a synthetic, highly modified peptide derived from the alpha-melanocyte-stimulating hormone. It has undergone rigorous clinical trials to explore its potential treatment for hypoactive sexual desire disorder (HSDD) in both men and women, as well as for acute hemorrhage. PT-141 stimulates the melanocortin-4 and melanocortin-1 receptors, showing promise in enhancing sexual arousal and stimulating the immune system.
What is PT-141?
PT-141, often referred to as the "female Viagra," gained attention during Phase IIb clinical trials designed to treat female hypoactive sexual desire disorder (HSDD). It primarily binds to the melanocortin 4 (MC-4R) and melanocortin 1 (MC-1R) receptors. In 2009, this melanocortin peptide was included in research for the potential treatment of acute hemorrhage. Notably, PT-141 is derived from Melanotan 2 (MT-2), another synthetic melanocortin.
Pt-141 | Peptide
Freedom Research
PT-141 is usually administered via subcutaneous injection at a dose of 1.75 mg, about 45 minutes to 1 hour before sexual activity. It should not be used more than once within 24 hours. No more than 8 doses are recommended per month. Always consult a healthcare provider for proper guidance and dosage.